van de Loosdrecht, A. A. http://orcid.org/0000-0001-8311-983X
Cremers, E. M. P.
Alhan, C.
Duetz, C.
in ’t Hout, F. E. M.
Visser-Wisselaar, H. A.
Chitu, D. A.
Verbrugge, A.
Cunha, S. M.
Ossenkoppele, G. J.
Janssen, J. J. W. M.
Klein, S. K. http://orcid.org/0000-0001-8847-2704
Vellenga, E.
Huls, G. A.
Muus, P.
Langemeijer, S. M. C.
de Greef, G. E.
te Boekhorst, P. A. W.
Raaijmakers, M. H. G.
van Marwijk Kooy, M.
Legdeur, M. C.
Wegman, J. J.
Deenik, W.
de Weerdt, O.
van Maanen-Lamme, T. M.
Jobse, P.
van Kampen, R. J. W.
Beeker, A.
Wijermans, P. W.
Biemond, B. J.
Tanis, B. C.
van Esser, J. W. J.
Schaar, C. G. http://orcid.org/0000-0002-2730-9353
Noordzij-Nooteboom, H. S.
Jacobs, E. M. G.
de Graaf, A. O.
Jongen-Lavrencic, M.
Stevens-Kroef, M. J. P. L.
Westers, T. M.
Jansen, J. H.
Funding for this research was provided by:
KWF Kankerbestrijding (2008-4333, 2008-4333)
This study was financially supported by BMS/Celgene and Roche. BMS/Celgene and Roche had no role in the design, analysis and interpretation of the results nor in writing of the article
Article History
Received: 30 June 2023
Revised: 11 January 2024
Accepted: 17 January 2024
First Online: 31 January 2024
Competing interests
: AL: research support: Celgene/BMS, Roche, Alexion; advisory boards: Celgene/BMS, Amgen, Novartis, Pfizer, AbbVie, Syros; speakers fee: Celgene/BMS, Novartis, Takeda. PM: advisory boards: Novartis; speakers fee: Sobi. PB: advisory boards: AbbVie; speakers fee: Novartis. JJ: research support: Novartis, BMS. President, Apps for Care and Science, nonprofit. foundation supported by Amgen, Astellas, Daiichi-Sankyo, Janssen, Olympus, Incyte, BMS, Sanofi Genzyme, Servier, Jazz, Takeda. Honoraria: Abbvie, Novartis, Pfizer, Incyte. All other authors declared no conflicts of interest.